August 19, 2013 / 12:31 PM / 6 years ago

CORRECTED-GTx says muscle drug fails in late-stage trials

(Corrects the number of patients to “about 650” from “about 325”)

Aug 19 (Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials.

A 3-mg dose of the drug, enobosarm, was tested on about 650 patients with non-small cell lung cancer - the most common form of lung cancer.

There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below